Curriculum Vitae

Personal Data

Title	Univ.-Prof., Dr.med.univ.
First name	Christoph K.
Name	Stein-Thoeringer (né Thoeringer)
Current position	Professor for Infectious Diseases and Translational Microbiome Research
Current institution(s)/site(s), country	Innere Medizin I & M3 Research Institute, University Clinic Tübingen, Germany
Identifiers/ORCID	0000-0002-8020-6986

Qualifications and Career

Stages	**Periods and Details**
Degree programme	Humanmedizin, Med. University Graz and Med. Fakultät, University of Zurich (1997-2005)
Doctorate	11/2005, M.D.; MD thesis, Max Planck Institute of Psychiatry, Munich, Germany
Stages of academic/ professional career	2022-now: Professor & senior attending physician, Innere Medizin I & M3 Research Institute, University Clinic Tübingen, Germany 2019-2022: Principal investigator / research group leader, Research Division Microbiome and Cancer (Director Prof. E. Elinav) German Cancer Research Center (DKFZ), Heidelberg, Germany 2020-2022: Attending physician, Department of Medical Oncology, National Center for Tumor Diseases (NCT) & University Hospital Heidelberg (Director Prof. D. Jäger) 2020-2022: Member, Board of Directors, National Center for Tumor Diseases (NCT), Heidelberg, Germany 2016-2018: Postdoctoral scientist, Immunology Program, Memorial Sloan Kettering Cancer Center (MSKCC), USA; Supervisor: Dr. Marcel van den Brink 2012-2019: Principal investigator / research group leader & resident physician, Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Germany; Supervisor: Dr. Roland M. Schmid 2010-2012: Resident physician, Max Planck Institute of Psychiatry, Munich, Germany (Director Prof. F. Holsboer) 2006-2009: Postdoctoral scientist, Max Planck Institute of Psychiatry, Munich, Germany; Supervisor: Dr. Carsten Wotjak

Supplementary Career Information:

Summary on an unconventional career path. I began my career as neuroscientist and full-time psychiatrist at the Max Planck Institute of Psychiatry, but completed my medical training and specialization as full-time resident in internal medicine in 2019. My clinical training and research in neuroscience fostered by my former mentor Dr. Wotjak gave me the best opportunity to establish a unique skill set in laboratory animal work as neurobehavioral and neurosurgical work with mice demands an ultimate level of understanding preclinical research. This helped me to

develop excellence in other fields of laboratory animal work such as immunooncology and T cell transfer models which is highly relevant for this proposal. During my residency in internal medicine, I became intrigued with basic and translational microbiome sciences. With support from my former supervisor Prof. R. Schmid (Director, Depart. Internal Medicine II, Techn. Univ. Munich – a leading center in gastroenterology in Germany), I established an independent research group investigating the role of the gut microbiome in colitis and functional GI disorders. At the end of my physician – scientist, medical residency, I joined the lab of Prof. M. van den Brink at MSKCC, New York, co-mentored by Prof. E. Pamer, to investigate the role of the gut microbiome in T cell driven immunooncology, an intriguing field in medicine with tremendous hope and future. After three years of a highly successful postdoc with an enormous expansion of my microbiome research skills including gnotobiotic and bioinformatic work, I was recruited in 2019 to the DKFZ as independent research group leader within the research division Microbiome and Cancer headed by Prof. E. Elinav. Through Eran's mentoring, microbiome research skills were brought to excellence, especially in the field of translational microbiome research. In 2022, I was appointed Professor for Infectious Diseases and Translational Microbiome Research to the University Hospital Tübingen, and continue my research on the gut microbiome, CAR-T cell immunotherapy and infections in immunocompromised hosts.

Activities in the Research System:

- **Grant reviewing activities for**

DFG, ÖAW, SNF, ISF, ERC, DZIF, Krebshilfe, CDG, BZKF, ASTCT, ANR, KWF, EKFS, ASTCT, IRIS.

- **Manuscript peer reviewing activities for**

Blood, Blood Advances, Cell, Cell Metabolism, Cell Reports, Clinical Infectious Diseases, Gastroenterology, Gastro Advances, Genome Medicine, Gut, Gut Microbes, eBioMedicine, mSystems, Nature Reviews Gastroenterology, Nature Cell Biology, Nature Communications, Nature Immunology, Nature Metabolism, NPJ Biofilmes and Microbiomes, Mucosal Immunology, iScience, JITC.

Supervision of Researchers in Early Career Phases:

2022-: Supervision of 6 postdocs, 4 PhD students, 4 MD students (MD thesis), 2 Bachelor students.
2019-2022: Supervision of 3 postdocs, 4 master students at DKFZ; from Biology, Biochemistry and Medical Sciences
2011-2019: Supervision of 2 postdocs, 2 PhD student, 4 MD students, 3 Master students at the Technical University of Munich; from Biology, Biochemistry, Nutrition Sciences.

Scientific Results

Category A – Articles in peer-reviewed journals:

1. **Stein-Thoeringer CK**, Renz BW, De Castilhos J, von Ehrlich-Treuenstätt V, Wirth U, Tschaidse T, Hofmann FO, Koch DT, Beirith I, Ormanns S, Guba MO, Angele MK, Andrassy J, Niess H, D'Haese JG, Werner J, Ilmer M. Microbiome Dysbiosis With Enterococcus Presence in the Upper Gastrointestinal Tract Is a Risk Factor for Mortality in Patients Undergoing Surgery for Pancreatic Cancer. ***Ann Surg.*** 2025;281(4):615-623.

2. Prasad R, Rehman A, Rehman L, Darbaniyan F, Blumenberg V, Schubert ML, Mor U, Zamir E, Schmidt S, Hayase T, Chang CC, McDaniel L, Flores I, Strati P, Nair R, Chihara D,

Fayad LE, Ahmed S, Iyer SP, Wang M, Jain P, Nastoupil LJ, Westin J, Arora R, Turner J, Khawaja F, Wu R, Dennison JB, Menges M, Hidalgo-Vargas M, Reid K, Davila ML, Dreger P, Korell F, Schmitt A, Tanner MR, Champlin RE, Flowers CR, Shpall EJ, Hanash S, Neelapu SS, Schmitt M, Subklewe M, Francois-Fahrmann J, **Stein-Thoeringer CK**, Elinav E, Jain MD, Hayase E, Jenq RR, Saini NY. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. ***Blood.*** 2025;145(8):823-839.

3. de Castilhos J, Tillmanns K, Blessing J, Laraño A, Borisov V, **Stein-Thoeringer CK**. Microbiome and pancreatic cancer: time to think about chemotherapy. ***Gut Microbes.*** 2024;16(1):2374596.

4. Maier L, **Stein-Thoeringer C**, Ley RE, Brötz-Oesterhelt H, Link H, Ziemert N, Wagner S, Peschel A. Integrating research on bacterial pathogens and commensals to fight infections-an ecological perspective. ***Lancet Microbe.*** 2024;5(8):100843.

5. **Stein-Thoeringer CK**, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. ***Nat Med.*** 2023;29(4):906-916.

6. Suez J, Cohen Y, Valdés-Mas R, Mor U, Dori-Bachash M, Federici S, Zmora N, Leshem A, Heinemann M, Linevsky R, Zur M, Ben-Zeev Brik R, Bukimer A, Eliyahu-Miller S, Metz A, Fischbein R, Sharov O, Malitsky S, Itkin M, Stettner N, Harmelin A, Shapiro H, **Stein-Thoeringer CK,** Segal E, Elinav E. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. ***Cell.*** 2022;185(18):3307-3328.e19.

7. Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, **Stein-Thoeringer CK**, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. ***Cell Rep Med.*** 2022;3(11):100720.

8. Docampo MD, da Silva MB, Lazrak A, Nichols KB, Lieberman SR, Slingerland AE, Armijo GK, Shono Y, Nguyen C, Monette S, Dwomoh E, Lee N, Geary CD, Perobelli SM, Smith M, Markey KA, Vardhana SA, Kousa AI, Zamir E, Greenfield I, Sun JC, Cross JR, Peled JU, Jenq RR, **Stein-Thoeringer CK***, van den Brink MRM*. Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease. ***Blood.*** 2022;139(15):2392-2405. *co-last authors

9. Cullin N, Azevedo Antunes C, Straussman R, **Stein-Thoeringer CK**, Elinav E. Microbiome and cancer. ***Cancer Cell***. 2021;39(10):1317-1341.

10. **Stein-Thoeringer CK**, Peled JU, Nichols KB, Lazrak A, Docampo M, Slingerland AE, Slingerland JB, Armijo G, Gomes A, Shono Y, Staffas A, Burgos da Silva M, Devlin S, Markey K, Bajic D, Tsakmaklis A, Littmann ER, Pastore A, Taur Y, Monette S, Arcila ME, Cross JR, Maloy M, Wright RJ, Amoretti LA, Fontana E,, Weber D, Sung AD, Hashimoto D, Xavier J, Mesina JA, Romero K, Lew M, Bush A, Bohannon L, Hayasaka K, Hasegawa K, Vehreschild MJGT, Ponce DM, Perales MA, Giralt SA, Jenq RR, Teshima T, Holler E, Chao NJ, Pamer EG, van den Brink MRM. Lactose drives Enterococcus expansion to promote graft-versus-host disease. ***Science***,

2019, 366:1143-1149.

Category B – Any other form of published results

Staudt S, Nikolka F, Perl M, Franz J, Leblay N, Yuan XK, Larrayoz M, Lozano T, Warmuth L, Fante MA, Skorpskaite A, Fei T, Bromberg M, San Martin-Uriz P, Rodriguez-Madoz JR, Ziegler-Martin K, Adil-Gholam N, Benz P, Tran Huu P, Freitag F, Riester Z, **Stein-Thoeringer C**, Schmitt M, Kleigrewe K, Weber J, Mangold K, Ho P, Einsele H, Prosper F, Ellmeier W, Busch D, Visekruna A, Slingerland J, Shouval R, Hiller K, Lasarte JJ, Martinez-Climent JA, Pausch P, Neri P, van den Brink M, Poeck H, Hudecek M, Luu M. Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells. ***bioRxiv*** 2025: 2024.08.19.608538; doi: 10.1101/2024.08.19.608538.

Academic Distinctions

- **Fellowships and Awards**

2018: New investigator award, American Society for Transplantation and Cellular Therapy (60.000,00 USD)
2016: Fellowship, German Research Foundation (DFG); funding for 2y-postdoc at MSKCC
2009: Research award, Association of Neuropsychopharmacology Germany (10.000,00 EUR)
2006: Postdoc fellowship, Max Planck Society (2006-2009)
2005: Research award, Initiative for Brain Research in Styria (INGESt.), Austria (5.000,00 EUR)
2004: Travel grant, Glaxo-Smith-Kline Foundation, Germany
2003: DOC stipend, Austrian Academy of Sciences (2003-2004)
2001: Exchange stipend of the University of Zurich (2001-2002)

Data protection and consent to the processing of optional data

If you provide voluntary information (marked as optional) in this CV, your consent is required. Please confirm your consent by checking the box below.

[X] **I expressly consent to the processing of the voluntary (optional) information, including "special categories of personal data" in connection with the DFG's review and decision-making process regarding my proposal.** This also includes forwarding my data to the external reviewers, committee members and, where applicable, foreign partner organisations who are involved in the decision-making process. To the extent that these recipients are located in a third country (outside the European Economic Area), I additionally consent to them being granted access to my data for the above-mentioned purposes, even though a level of data protection comparable to EU law may not be guaranteed. For this reason, compliance with the data protection principles of EU law is not guaranteed in such cases. In this respect, there may be a violation of my fundamental rights and freedoms and resulting damages. This may make it more difficult for me to assert my rights under the General Data Protection Regulation (e.g. information, rectification, erasure, compensation) and, if necessary, to enforce these rights with the help of authorities or in court.

I may **revoke** my consent in whole or in part at any time – with effect for the future, freely and without giving reasons – vis-à-vis the DFG (postmaster@dfg.de). The lawfulness of the processing carried out up to that point remains unaffected. Insofar as I transmit "special categories of personal data" relating to third parties, I confirm that the necessary legitimation under data protection law exists (e.g. based on consent).

I have taken note of the DFG's Data Protection Notice relating to research funding, which I can access at www.dfg.de/privacy_policy and I will forward it to such persons whose data the DFG processes as a result of being mentioned in this CV.